Retirement Systems of Alabama Sells 9,618 Shares of Hologic, Inc. (NASDAQ:HOLX)

Retirement Systems of Alabama lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 709,391 shares of the medical equipment provider's stock after selling 9,618 shares during the quarter. Retirement Systems of Alabama owned about 0.32% of Hologic worth $43,819,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Blue Trust Inc. grew its holdings in Hologic by 26.8% during the 1st quarter. Blue Trust Inc. now owns 7,637 shares of the medical equipment provider's stock valued at $472,000 after buying an additional 1,616 shares in the last quarter. Redwood Wealth Management Group LLC purchased a new position in Hologic during the 1st quarter valued at approximately $3,534,000. Insigneo Advisory Services LLC grew its holdings in Hologic by 6.1% during the 1st quarter. Insigneo Advisory Services LLC now owns 6,428 shares of the medical equipment provider's stock valued at $397,000 after buying an additional 367 shares in the last quarter. BDF Gestion grew its holdings in Hologic by 143.4% during the 1st quarter. BDF Gestion now owns 54,312 shares of the medical equipment provider's stock valued at $3,355,000 after buying an additional 32,000 shares in the last quarter. Finally, Hanson & Doremus Investment Management purchased a new position in Hologic during the 1st quarter valued at approximately $99,000. Institutional investors own 94.73% of the company's stock.

Hologic Trading Down 0.1%

Shares of HOLX stock traded down $0.05 on Monday, reaching $64.43. 3,148,461 shares of the company's stock were exchanged, compared to its average volume of 2,352,922. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $14.36 billion, a PE ratio of 27.19, a P/E/G ratio of 2.36 and a beta of 0.55. The company's fifty day simple moving average is $59.41 and its 200 day simple moving average is $64.21.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company earned $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on HOLX shares. Morgan Stanley cut their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Evercore ISI dropped their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Stephens dropped their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $77.42.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.